Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Serono's Rebif reaches blockbuster status for first time

    This is a preview of subscription content, log in to check access.

    Rights and permissions

    Reprints and Permissions

    About this article

    Cite this article

    Serono's Rebif reaches blockbuster status for first time. Pharmacoecon. Outcomes News 465, 11 (2004). https://doi.org/10.2165/00151234-200404650-00031

    Download citation

    Keywords

    • Public Health
    • Health Outcome
    • Health Economic
    • Outcome News
    • Drug Company